Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of MIT-001 in Prevention of Oral Mucositis in Patients Receiving CCRT for Locally Advanced HNSCC

NCT04651634 is registered in ClinicalTrials.gov with MitoImmune Therapeutics as lead sponsor.

NCT NCT04651634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04651634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of MIT-001 in Prevention of Oral Mucositis in Patients Receiving CCRT for Locally Advanced HNSCC
Lead sponsor
MitoImmune Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 21, 2021
Completion date
December 31, 2025
Enrollment
60 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, oral mucositis